Kalvista Pharmaceuticals Inc

CUSIP 483497103COMKALVQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

14.0%

Max % of class reported

Institutional Holders

176

13F filers (latest quarter)

76 filings · latest Jan 13, 2026

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	Jan 13, 2026	Point72 Asset Management, L.P.	13G/A	5.5%	2.78M	SEC
2	Jan 12, 2026	Point72 Asset Management, L.P.	13G	4.9%	2.52M	SEC
3	Dec 30, 2025	Integrated Core Strategies (Us) LLC	13G/A	11.0%	2.96M	SEC
4	Nov 14, 2025	Vestal Point Capital, LP	13G/A	1.5%	750.0K	SEC
5	Nov 10, 2025	Millennium Management LLC	13G	11.0%	2.53M	SEC
6	Nov 4, 2025	Frazier Life Sciences Public Fund, L.P.	13D/A	6.9%	—	SEC
7	Aug 20, 2025	Frazier Life Sciences Public Fund, L.P.	13D/A	4.8%	—	SEC
8	May 15, 2025	Tang Capital Management, LLC	13G/A	9.9%	4.94M	SEC
9	May 13, 2025	Capital World Investors	13G/A	6.4%	3.18M	SEC
10	Nov 14, 2024	Tang Capital Management LLC	13G/A	10.0%	4.32M	SEC

See the full Schedule 13D/13G history for Kalvista Pharmaceuticals Inc.

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Venrock Adviser, LLC	6.47M	$130.33M
2	Frazier Life Sciences Management, L.P.	4.96M	$99.87M
3	Suvretta Capital Management, LLC	4.77M	$95.99M
4	Tang Capital Management LLC	4.57M	$92.07M
5	Blackrock, Inc.	3.80M	$76.41M
6	Silverarc Capital Management, LLC	2.88M	$57.90M
7	Capital World Investors	2.81M	$56.54M
8	Point72 Asset Management, L.P.	2.14M	$43.02M
9	State Street Corp	1.96M	$39.37M
10	Millennium Management LLC	1.91M	$38.49M